Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The bill lets terminally ill patients request access to drugs the FDA hasn't yet approved without going through the agency. Patients can request the drugs from manufacturers if the medicine has gone through a small-scale clinical trial and is still under FDA consideration (must have passed Phase 1).
FOCUS AND ICC WILL NOW BE IN PLAY. Market $360M to $1.2B annually.
Glad they ramped up supply! You know, economies of scale.
DO YOU HAVE A LINK????
No. It was the 28th annual Oppenheimer something or another.
I think next week she presents at the 2018 Snake Bit Conference, so there’s that.
Thank you, kind sir.
These things have a way of working themselves out.
I think.
As long as you are sitting on my shoulder eating dates a la Indiana Jones, life will be beautiful.
Much better than owning DCTH, I’ll tell you that for nothing.
No worries. I hope I didn’t offend.
Love it. By the way, I’d give my left hand to read Sam’s...
Too rich for my blood.
Does the delcath.org site plan owner plan on becoming more transparent? I’d like to know who is running it. A bio, etc.
It would be helpful to have a central hub for shareholders to discuss, share ideas, etc.
Right now it’s a bit to mysterious for me.
I don’t recall exactly but it was at least 2 days.
Do you also like long walks on the beach and classical music? Hahaha
You make me sad sometimes. I hope your life outside of this message board is bountiful.
Yep. Weather.
Haircut coming.
Was the Oppenheimer Conference canceled?
Is there a link to the webcast?
Brutal. Where are shares coming from? This isn’t retail and leak out is through April.
James is short.
Wait, you bought 2 days ago James. Why the sudden turn???
HULK NO SEE BTIG
When could retail start trading? 8-10th all had Fail to Deliver data. On 20 November 1.3M shares reported Fail to Deliver @ $.65. That’s $800k and change.
Again, you know me and my share count history when trying to determine when dilution was over, so maybe please feel free to do the analysis as well.
Experience it real time. Lol. I’m crying.
H20 has a point. Get some skin in the game, Sam, before I make you green eggs and ham!!!
Shoot, if ever we needed someone who truly believed DCTH is worth $370 a share, it’s now!
Well, I believe my numbers to be accurate but anyone please free to confirm or correct them.
At this point, no clue who may have been behind the naked shorting (assuming the Fail to Deliver shares were all naked short interest—which is not always the case). I suggest reading about Fail to Deliver data on the SEC’s website.
With the above caveats, Ayerton, HB and the mysterio 181M share purchasers certainly dodged a bullet: only 300,000 shares were reported as Fail to Deliver in February—a far cry from the 33M shares flagged in the preceding three months.
Data for the 1st 2 weeks of March has not yet been reported. if the Fail to Deliver data shows no measurable increase, it will be interesting to see what FINRA’s Equity Short Interest report reveals. BTIG arrived on the scene right around this time.
It sure would be nice to spend time enjoying capital appreciation instead of playing detective, that’s for sure.
GLTYA.
There were 33M DCTH shares (valued at over $2.9M) reported as Fail to Deliver by the SEC between 11/6/17 and 1/26/2018.
I filed a FOIA requests with the SEC regarding these transactions.
Hey James, posting that link all over the place, lol. Last night you bought. Today you sell.
NEVER!!!
All this other BS? Lol. What are you talking about?
You bought yesterday per your post last night!!!
Now you are selling????
I can’t wait to catch you in a squeeze.
HULK WANT POWER HOUR.
HULK NO CARE IF PUNY.
LoL. Crackerjack website. Hey Cr8tive007, you admitted yesterday you bought DCTH based on posts from Matt74, today you are pimping barchart. Do you realize how completely nonsensical and contradictory that is?
Jenny can’t keep going to these dog and pony shows with such an embarrassingly low PPS, IMO.
Green is coming.
My opinion only.
Duly noted. I think.
Full Disclosure - I DON'T CARE.
My last prediction was that the 10K would drop on March 16th. What, whaaaaat?
Ugh, wait, my stomach...it hurts. I feel like I'm about to REGURGITATE some "old data" (4 days ago):
* Revenue from European sales for 2017 increased 35%;
* Satisfaction of all obligations under the privately placed senior secured convertible notes issued to two institutional investors in June 2016;
* Completed a $5.0 million capital raise in February 2018;
Modified the Special Protocol Agreement (SPA) with the U.S. Food and Drug Administration (FDA) for the Company’s Phase 3 clinical trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) to treat patients with hepatic dominant ocular melanoma (OM);
* Secured a commercial supply of melphalan through an agreement with Tillomed Laboratories for use with the company’s CHEMOSAT® Delivery System for Melphalan, where it is marketed in Europe for the treatment of a wide range of cancers of the liver.
Yeah, DCTH has all the hallmarks of a total failure.
But hey, I'm not an "accredited investor" (insert eye roll and snicker), so what do I know? Other than if I were an "accredited investor" I would not be pontificating about the perils of a stock currently trading at $.012 when, full disclosure, I have no position.
I told you from day one I am long on DCTH. Am I getting POUNDED by DCTH right now? YES! Have I had a baptism by FIRE? YES! Does this, at present, really suck? YES!
I am not a trader. I buy and hold and the only prediction I will make is that every day you try to save us "loss souls" (clever) brings us closer to FDA approval (can I get an AMEN???)
And sir, I would never mock you. We'll just have to agree to disagree!
Do you ever see sunshine?
DCTH $1.25M run rate per month in 2017. You are tacking on an imaginary $750,000 a month,
which in the aggregate, is close to $9M over 12 months. Get outta here.
You are flat out making these numbers up.
I know you know how to read, Sam. If not, I’ll make you green eggs and ham.
My best and only advice: I suggest buying at a time that’s best for you and you only.
I’d LOVE LOVE LOVE to read this response!
Isn’t it a little early for the 2018
Darwin Awards?
I swear I keep hearing a bitter tasting vegetable—a turnip—yapping incessantly.
In any event, wasn’t Oppenheimer the original underwriting firm for the private offering before ROTH took over?
I also loom at the presentation as a positive for DCTH:
“Investors will have the opportunity to hear and meet with over 100 company management teams in 1on1 and small group meetings. We anticipate that this will, once again, be one of the most important investor conferences in this sector.”
Clearly, ‘over 100’ companies won’t be presenting, so maybe it won’t be a ‘nonevent’, you know, like a talking, bitter turnip.
Peculiar time to start her presentation at Oppenheimer’s 28th Annual Healthcare Conference on Wednesday.